한국인의 폐암에서 TP53 유전자 변이 분석
Analysis of TP53 Gene Mutations in the Korean Patients with Lung Cancer
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: Lung cancer is one of the leading causes of cancer-related deaths throughout the world. The gene tumor protein 53 (TP53) is frequently mutated in cases of lung cancer. This study was performed to investigate the frequencies and types of mutations in the TP53 gene in Korean patients with lung cancer. Methods: We obtained tissue samples from 80 lung cancer patients and synthesized TP53 cDNA by using RNA isolated from these tissues by performing reverse transcriptase polymerase chain reaction. Hybridization and denaturing high-performance liquid chromatography were performed to identify the TP53 gene mutations, and then, the mutations were validated by direct sequencing. Results: Forty mutations out of the 80 patients (50.0%) were noted in the TP53 gene. The frequencies of TP53 gene mutation for different cancer types, namely, squamous cell carcinoma, adenocarcinoma, and small cell carcinoma were 61.1%, 27.3%, and 26.7%, respectively. The mutation frequencies in the different regions of the gene were 10.0% for exon 4, 35.0% for exon 5, 12.5% for exon 6, 22.5% for exon 7, 17.5% for exon 8,and 2.5% for exon 9. The frequently mutated positions were codon 179 in exon 5, codons 202 and 220 in exon 6, and codons 266 and 273 in exon 8. Conclusions: Exon 5 was the most frequently mutated region in the TP53 gene. Compared to the patients with the other types of cancers, patients with squamous cell carcinoma showed a higher frequency of TP53 mutation. Codon 179 was the most frequently mutated codon in the TP53 gene.
Abstract
Background: Lung cancer is one of the leading causes of cancer-related deaths throughout the world. The gene tumor protein 53 (TP53) is frequently mutated in cases of lung cancer. This study was performed to investigate the frequencies and types of mutations in the TP53 gene in Korean patients with lung cancer. Methods: We obtained tissue samples from 80 lung cancer patients and synthesized TP53 cDNA by using RNA isolated from these tissues by performing reverse transcriptase polymerase chain reaction. Hybridization and denaturing high-performance liquid chromatography were performed to identify the TP53 gene mutations, and then, the mutations were validated by direct sequencing. Results: Forty mutations out of the 80 patients (50.0%) were noted in the TP53 gene. The frequencies of TP53 gene mutation for different cancer types, namely, squamous cell carcinoma, adenocarcinoma, and small cell carcinoma were 61.1%, 27.3%, and 26.7%, respectively. The mutation frequencies in the different regions of the gene were 10.0% for exon 4, 35.0% for exon 5, 12.5% for exon 6, 22.5% for exon 7, 17.5% for exon 8,and 2.5% for exon 9. The frequently mutated positions were codon 179 in exon 5, codons 202 and 220 in exon 6, and codons 266 and 273 in exon 8. Conclusions: Exon 5 was the most frequently mutated region in the TP53 gene. Compared to the patients with the other types of cancers, patients with squamous cell carcinoma showed a higher frequency of TP53 mutation. Codon 179 was the most frequently mutated codon in the TP53 gene.
참고문헌 (24)
- Minna JD, "Lung cancer: principles and practice", pp.143~148 (1996), Lippincott-Raven
- Mendelsohn J, "Targeting the epidermal growth factor receptor for cancer therapy", J Clin Oncol, 20(18), pp.1~13 (2002)
- Sozzi G, "Loss of FHIT function in lung cancer and preinvasive bronchial lesions", Cancer Res, 58, pp.5032~5037 (1998)
- Mao L, "Recent advances in the molecular diagnosis of lung cancer", Oncogene, 21, pp.6960~6969 (2002)
- Oliver M, "TP53 mutations in human cancers: origins, consequences, and clinical use", Cold Spring Harb Perspect Biol, 2 (2010)
- Hainaut P, "p53 and human cancer: the first ten thou-sand mutations", Adv Cancer Res, 77, pp.81~137 (2000)
- Vogelstein B, "Surfing the p53 network", Nature, 408, pp.307~310 (2000)
- Pfeifer GP, "Mutational spectra of human cancer", Hum Genet, 125, pp.493~506 (2009)
- Jassem E, "Types and localisation of p53 gene mutations: a report on 332 non-small cell lung cancer patients", Lung Cancer, 34(2), pp.47~51 (2001)
- Feng Z, "Chromium(VI) exposure enhances polycyclic aromatic hydrocarbon-DNA binding at the p53 gene in human lung cells", Carcinogenesis, 24, pp.771~778 (2003)
- Pfeifer GP, "Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers", Oncogene, 21, pp.7435~7451 (2002)
- Hussain SP, "Mutability of p53 hotspot codons to benzo(a)pyrene diol epoxide (BPDE) and the frequency of p53 mutations in nontumorous human lung", Cancer Res, 61, pp.6350~6355 (2001)
- 이응배, "TP53 Mutations in Korean Patients with Non-small Cell Lung Cancer", Journal of Korean Medical Science, 25(5), pp.698~705 (2010), 대한의학회
- Walker DR, "Evolutionary conservation and somatic mutation hotspot maps of p53: correlation with p53 protein structural and functional features", Oncogene, 18, pp.211~218 (1999)
- Kato S, "Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis", Proc Natl Acad Sci USA, 100, pp.8424~8429 (2003)
- Takahashi T, "p53: a frequent target for genetic abnormalities in lung cancer", Science, 246, pp.491~494 (1989)
- Hu Y, "The p53 codon 72 proline allele is associated with p53 gene mutations in non-small cell lung cancer", Clin Cancer Res, 11, pp.2502~2509 (2005)
- Sidransky D, "Clinical implications of the p53 gene", Annu Rev Med, 47, pp.285~301 (1996)
- Horio Y, "Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer", Cancer Res, 53, pp.1~4 (1993)
- Hashimoto T, "Different subtypes of human lung adenocarcinoma caused by different etiological factors. Evidence from p53 mutational spectra", Am J Pathol, 157, pp.2133~2141 (2000)
- "International Agency for Research on Cancer. IARC tp53 database, R15" (2010)[URL]
- Hernandez-Boussard TM, "specific spectrum of p53 mutations in lung cancer from smokers: review of mutations compiled in the IARC p53 database", Environ Health Perspect, 106, pp.385~391 (1998)
- Bennett WP, "Molecular epidemiology of human cancer risk: gene-environment interactions and p53 mutation spectrum in human lung cancer", J Pathol, 187, pp.8~18 (1999)
- pyrene and lung cancer: a reply, "Mutagenesis", 1998, 537~538